Welcome to BioSeeker Group!

Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors

Additional Information

Published Date May 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5747
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors.

    To find out more about Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

This Report Includes the Following Companies:
4SC
AB Science
Abbott
Abiogen
Acceleron Pharma
Access
ACT Biotech
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agennix
Aida Pharmaceuticals
Alethia Biotherapeutics
Allist Pharmaceuticals
Allostera
Alnylam
AlphaVax
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Anza Therapeutics
Apogee Biotechnology
Apotex
Arana Therapeutics
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
AVI BioPharma
Avila Therapeutics
Bavarian Nordic
Bayer
Benitec
Berkeley Lab
Betapharma
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
Bionovo
BioNumerik
BioSante
Biotecnol
Biotica Technology
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Callisto Pharmaceuticals
Cambrex
CanBas
Cancer Advances
Cancer Research Technology
Catalyst Biosciences
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CerRx
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cornerstone Pharmaceuticals
CritiTech
Cue Biotech
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokine PharmaSciences
Cytokinetics
Cytopia
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dyax
EGEN Inc
Eisai
Elara Pharmaceuticals
Eli Lilly
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
FibroGen
Five Prime Therapeutics
Galapagos
Galectin Therapeutics
Galena Biopharma
GammaCan
Generex
Genmab
Genta
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GPC Biotech
Green Cross
Hanmi
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hy BioPharma
Hypha Discovery
Idera Pharmaceuticals
ImClone Systems
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incozen Therapeutics
Incyte Corporation
Inhibiton Therapeutics
Innate Pharma
Innovive
Inovio
Insmed
Insys Therapeutics
Intellikine
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
ISU ABXIS
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
KaloBios
Kalypsys
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
Kringle Pharma
KuDOS
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Lexicon Pharmaceuticals
Ligand
Lorus Therapeutics
Marina Biotech
MAT Biopharma
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
MolMed
Morvus Technology
Myrexis
Nano Terra
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
NewSouth Innovations
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
Noxxon
Oasmia
Oncalis
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pathway Therapeutics
Patrys
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Portola Pharmaceuticals
Proacta
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
Protein Sciences
Protgen
Provid
PTC Therapeutics
QLT
Quantum Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samtheo Biopharma
Samyang
Sanofi
Santaris Pharma
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
SciClone Pharmaceuticals
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
SGX Pharmaceuticals
Shionogi
Shire
Silence Therapeutics
Simcere Pharmaceuticals
Spear Therapeutics
SRI International
Stainwei Biotech
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
SynDevRx
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Tau Therapeutics
TauTaTis
TCD Pharma
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
TransTech Pharma
Trion Pharma
UCB
UMN Pharma
VasGene Therapeutics
VaxOnco
VBL Therapeutics
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
VioQuest
ViroMed
Wyeth
Xcovery
Xencor
Xerion
Yakult Honsha
YM BioSciences
Zenyaku Kogyo
Zeria
A Shortlist of Drugs Included are:
A6
ABT-510
AC-480
AE-37
AEG-35156
AF-802
afatinib
aflibercept
AGS-1C4D4
alvocidib
AMG-386
Angiozyme
apatinib
apricoxib
AR-42
ARC-100
ARQ-197
AT-7519
AT-9283
atrasentan
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
bevacizumab
BEZ-235
BGT-226
BI-811283
BIBF-1120
BMS-690514
BMS-754807
BMS-777607
bosutinib
brivanib alaninate
brivudine
Cabozantinib
CAL-101
capecitabine
catumaxomab
CBP-501
CC-223
cediranib
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
CPI-613
crizotinib
CRLX-101
dacomitinib
dalotuzumab
danusertib
dasatinib
DI-17E6
dinaciclib
docetaxel
dovitinib lactate
doxorubicin
E-75
E-7820
endostatin
endoxifen
eniluracil
ENMD-2076
enzastaurin hydrochloride
erlotinib
everolimus
Exherin
foretinib
fosbretabulin tromethamine
fostamatinib disodium
ganitumab
gefitinib
GliaAtak
GSK-1120212
GSK-2118436
GT-111
GV-1001
GVAX
HBP-347
IC-83
icotinib hydrochloride
icrucumab
idronoxil
imatinib mesilate
IMP-321
INCB-028060
INSM-18
intetumumab
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
JI-101
KD032
KX2-391
L19-IL2
lapatinib ditosylate
lenvatinib
lestaurtinib
linifanib
linsitinib
LipoVIL12
LY-2090314
LY-2275796
masitinib
MetXia
MGCD-265
midostaurin
MK-1775
MKC-1
MLN-8237
MM-111
mocetinostat
motesanib diphosphate
motexafin gadolinium
muparfostat (IV)
MVA-BN Her-2 vaccine
nadroparin
neratinib
NGR-TNF
nilotinib
nimotuzumab
NPB-001-056
oblimersen sodium
olaparib
ON-01910
onartuzumab
OSI-027
OTS-102
P-276-00
P276-00
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
PD-0332991
pegdinetanib
pemetrexed disodium
pentamidine isethionate
perifosine
PF-4856884
PHA-848125AC
plitidepsin
ponatinib
ProstAtak
PTC-299
PX-12
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
ramucirumab
regorafenib
Rexin-G
ridaforolimus
rilotumumab
romidepsin
ruxolitinib
RX-0201
RX-0201-N
SCH-900776
seliciclib
selumetinib
siltuximab
sirolimus
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
talactoferrin alfa
talmapimod
talminogene laherparepvec
tandutinib
TAS-102
tasquinimod
TB-403
tegafur + uracil
telatinib
temsirolimus
Tenarad
terameprocol
thymalfasin
tigatuzumab
tipifarnib
tivozanib
tocilizumab
trabedersen
trastuzumab
TRC-105
triciribine phosphate
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
vemurafenib
vismodegib
volasertib
volociximab
vosaroxin
WX-671
XL-147
XL-184
XL-281
XL-413
XL-647
XL-765
Z-360

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors.
    To find out more about Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Melanoma and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Apoptosis. Learn More


Triple Analysis: Breast Cancer, Colorectal Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Colorectal Cancer and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Apoptosis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Learn More


Triple Analysis: Lymphoma, Melanoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the compound strategy of Antibodies. Learn More